Drug development, clinical trials, and industry dynamics—what changes timelines, risk, and competitive positioning.
Takeda Pharmaceutical Company has officially ended its partnership with Veritas In Silico, marking another step in its strategy to streamline collaborations.
Takeda Pharmaceutical Company has officially ended its partnership with Veritas In Silico, marking another step in its strategy to streamline collaborations.
READ MORE
Recent biopharma mergers and acquisitions have highlighted a shift where the workforce and talent acquisition are increasingly becoming the central asset rather than just the therapeutic products.
As the pharma industry steps into the Q1 earnings season, key themes include new revenue streams from oral GLP-1 medicines and ongoing challenges in regulatory and pricing landscapes.
Revolution Medicines announced breakthrough data showing a targeted pill nearly doubled survival in metastatic pancreatic cancer patients compared to chemotherapy.
Regeneron has entered the radiopharmaceutical arena with a strategic alliance valued at up to $4.3 billion with Telix, positioning the company to strengthen its oncology portfolio. Analysts highlight this as a significant move that broadens Regeneron's capabilities in targeted cancer therapies.
AbbVie has made a significant move into the pain medicine sector through a licensing agreement with China’s Haisco valued at up to $715 million. This marks AbbVie’s first foray into novel pain therapies, entering a market currently led by Vertex’s NaV1.8 inhibitor, Journavax.
Eli Lilly's launch of the oral obesity medication Foundayo marks a critical development in the competitive race against Novo Nordisk's established oral Wegovy, reshaping the pharmaceutical landscape for weight loss treatments.
The first quarter of 2026 reveals encouraging trends in the biopharmaceutical job market, suggesting a potential turnaround after previous challenges.
Merck has reduced its acquisition offer for Terns Pharmaceuticals by $1 billion following updated data on Terns’ leukemia treatment. This development signals a shift in valuation and dynamics within competitive pharma acquisitions in oncology.
Gilead Sciences has announced a major acquisition of German biotech Tubulis for over $3 billion, aiming to strengthen its oncology portfolio with innovative antibody-drug conjugates (ADCs).
Neurocrine Biosciences has acquired Soleno Therapeutics for $2.9 billion, gaining access to Vykat XR, a treatment for the rare genetic disorder Prader-Willi syndrome, expanding its rare disease portfolio.
